The field effectiveness of routine and emergency vaccination with an inactivated vaccine against foot and mouth disease

Vaccine

Volumn 31, Issue 6, 2013, Pages 879-885

  Elnekave, E ^a   Li, Y ^b   Zamir, L ^a   Even Tov, B ^c   Hamblin, P ^b   Gelman, B ^d   Hammond, J ^b   Klement, E ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b INSTITUTE FOR ANIMAL HEALTH   (United Kingdom)

^c Israeli Veterinary Services   (Israel)

^d KIMRON VETERINARY INSTITUTE   (Israel)

Author keywords

Efficacy; Inactivated vaccine; Neutralizing antibodies; NSP; R1 value

Indexed keywords

BRUCELLA VACCINE; FOOT AND MOUTH DISEASE VACCINE; INACTIVATED VACCINE; NEUTRALIZING ANTIBODY; NONSTRUCTURAL PROTEIN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; DRUG POTENCY; EMERGENCY CARE; EPIDEMIC; FOOT AND MOUTH DISEASE; IMMUNOASSAY; NONHUMAN; PRIORITY JOURNAL; SEROTYPE; VACCINATION; VIRUS STRAIN;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CATTLE; CATTLE DISEASES; DISEASE OUTBREAKS; FOOT-AND-MOUTH DISEASE; ISRAEL; TIME FACTORS; VACCINATION; VACCINES, INACTIVATED; VIRAL VACCINES;

EID: 84872597906     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.12.011     Document Type: Article

References (20)

1. Doel T.R. FMD vaccines. Virus Res 2003, 91(January (1)):81-99.
2. OIE. Foot and mouth disease. OIE terrestrial manual: OIE, 2012.
3. Parida S. Vaccination against foot-and-mouth disease virus: strategies and effectiveness. Expert Rev Vaccines 2009, 8(March (3)):347-365.
4. Cox S.J., Barnett P.V. Experimental evaluation of foot-and-mouth disease vaccines for emergency use in ruminants and pigs: a review. Vet Res 2009, 40(May-June (3)):13.
5. Halasa T., Boklund A., Cox S., Enoe C. Meta-analysis on the efficacy of foot-and-mouth disease emergency vaccination. Prev Vet Med 2011, 98(January (1)):1-9.
6. Barnett P.V., Pullen L., Williams L., Doel T.R. International bank for foot-and-mouth disease vaccine: assessment of Montanide ISA 25 and ISA 206, two commercially available oil adjuvants. Vaccine 1996, 14(September (13)):1187-1198.
7. Cox S.J., Carr B.V., Parida S., Hamblin P.A., Prentice H., Charleston B., et al. Longevity of protection in cattle following immunisation with emergency FMD A22 serotype vaccine from the UK strategic reserve. Vaccine 2010, 28(March (11)):2318-2322.
8. Dekker A., Terpstra C. Prevalence of foot-and-mouth disease antibodies in dairy herds in The Netherlands four years after vaccination. Res Vet Sci 1996, 61(July (1)):89-91.
9. Remond M., Kaiser C., Lebreton F.O., Moutou F., Cruciere C. Residual foot-and-mouth disease virus antibodies in French cattle and sheep six years after the vaccination ban. Vet Res 2001, 32(January-February (1)):81-86.
10. Terpstra C., Van Maanen C., Van Bekkum J.G. Endurance of immunity against foot-and-mouth disease in cattle after three consecutive annual vaccinations. Res Vet Sci 1990, 49(September (2)):236-242.
11. Woolhouse M.E., Haydon D.T., Pearson A., Kitching R.P. Failure of vaccination to prevent outbreaks of foot-and-mouth disease. Epidemiol Infect 1996, 116(June (3)):363-371.
12. Stram Y., Engel O., Rubinstein M., Kuznetzova L., Balaish M., Yadin H., et al. Multiple invasions of O1 FMDV serotype into Israel revealed by genetic analysis of VP1 genes of Israeli's isolates from 1989 to 2007. Vet Microbiol 2011, 147(January (3-4)):398-402.
13. Yadin H., Brenner J., Chai D., Oved Z., Hadany Y., Kusak A., et al. The NSP immune response of vaccinated animals after in-field exposure to FMDV. Vaccine 2007, 25(November (49)):8298-8305.
14. Barteling SJ, Yadin H, Sutmoller P. Discussion paper on guidelines for control of Foot-and-Mouth Disease (FMD) vaccine quality and performance in the field. Session of the Research Group of the Standing Technical Committee of EuFMD. Chania, Crete, Greece, 2004: Appendix 19.
15. Golding S.M., Hedger R.S., Talbot P. Radial immuno-diffusion and serum-neutralisation techniques for the assay of antibodies to swine vesicular disease. Res Vet Sci 1976, 20(March (2)):142-147.
16. Xu L., Bieker J., Rowland J., Hurtle W., Carrillo C., Yadin H., et al. Sequence identification and genetic profile of FMDV in an 2007 disease outbreak in Israel using full length genomic analysis. The Global control of FMD - Tools, ideas and ideals 2008, 211-216. Appendix 36.
17. Brehm K.E., Kumar N., Thulke H.H., Haas B. High potency vaccines induce protection against heterologous challenge with foot-and-mouth disease virus. Vaccine 2008, 26(March (13)):1681-1687.
18. Lannes N., Python S., Summerfield A. Interplay of foot-and-mouth disease virus, antibodies and plasmacytoid dendritic cells: virus opsonization under non-neutralizing conditions results in enhanced interferon-alpha responses. Vet Res 2012, 43(August (1)):64.
19. Cox S.J., Gubbins S., Barnett P.V. IL-6 production following vaccination in pigs--an additional immune response parameter for assessing FMD vaccine efficacy?. Vaccine 2011, 29(June (29-30)):4704-4708.
20. Parida S., Oh Y., Reid S.M., Cox S.J., Statham R.J., Mahapatra M., et al. Interferon-gamma production in vitro from whole blood of foot-and-mouth disease virus (FMDV) vaccinated and infected cattle after incubation with inactivated FMDV. Vaccine 2006, 24(February (7)):964-969.